Description: Clomiprimine (Anafranil) is a prescription drug belonging to the tricyclic antidepressants (TCAs) class which is primarily used to treat obsessive-compulsive disorder (OCD). It works by increasing the activity of certain chemicals in the brain, which helps to reduce obsessive-compulsive behaviors.
Serious Anafranil Side Effects
Serotonin syndrome is a possibly fatal syndrome that can be caused by Anafranil. Your risk may be greater if you take Anafranil with certain other medicines (e.g., “triptans,” MAOIs, SSRIs). Symptoms may include agitation; confusion; hallucinations; coma; fever; fast or irregular heartbeat; tremor; excessive sweating; and nausea, vomiting, or diarrhea.
Common Anafranil Side Effects
According to the FDA, the most common side effects of clomiprimine according to the Anafranil drug label reported by the FDA include:
Know Your Risk for Side Effects with the Rxight® PGx Testing Program
Rxight® pharmacogenetic testing> is designed to determine your inherited vulnerability for experiencing side effects of Anafrinil – even before you even start taking it. That way, you and your prescriber will know if it is safe, and what the dose should be. Additionally, the Rxight® PGx testing program provides an estimate of your ability to metabolize hundreds of other clinically relevant prescription and over-the-counter medications across dozens of medication classes. All that is required is a simple cheek swab of your DNA by a participating pharmacist, followed by a detailed analysis of your results to be shared with prescribers, thus providing you with a medication blueprint for life.
How Does Pharmacogenetic Testing Work?
Inter-individual differences in the genes that encode liver enzymes are what cause people to react to medication to differently. This is due to genetic variations in specific genes that encode enzymes in the liver which are responsible. As per Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (Mar 2017) regarding the use of pharmacogenomic tests in dosing of tricyclic antidepressants (TCAs), including clomipramine, 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 intermediate metabolizers. This variation can be understood by your prescriber, who can prescribe the medication in an effective and safe manner.
Contributors to this Article: Michael Sapko, MD, Phd and Deborah Kallick, PhD, Medicinal Chemistry
Read more about Rxight® pharmacogenetic testing